Apyx Medical Corporation (APYX)
After hours:
| Previous Close | 1.6000 |
| Open | 1.6200 |
| Bid | 1.5700 x 100 |
| Ask | 1.6600 x 100 |
| Day's Range | 1.5801 - 1.6245 |
| 52 Week Range | 1.2100 - 7.9700 |
| Volume | |
| Avg. Volume | 157,609 |
| Market Cap | 55.43M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook
CLEARWATER, Fla., May 09, 2024--Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024.
- Business Wire
Apyx Medical Corporation Announces Board Leadership Transition
CLEARWATER, Fla., May 09, 2024--Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024.
- Business Wire
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CLEARWATER, Fla., April 25, 2024--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th.
